{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T04:11:29Z","timestamp":1742098289040,"version":"3.38.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,12,10]],"date-time":"2011-12-10T00:00:00Z","timestamp":1323475200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1007\/s11033-011-1301-5","type":"journal-article","created":{"date-parts":[[2011,12,9]],"date-time":"2011-12-09T06:18:08Z","timestamp":1323411488000},"page":"5059-5067","source":"Crossref","is-referenced-by-count":4,"title":["Post-transcriptional silencing of Notch2 mRNA in chronic lymhocytic leukemic cells of B-CLL patients"],"prefix":"10.1007","volume":"39","author":[{"given":"Kaneez","family":"Fatima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rehan Zafar","family":"Paracha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishtiaq","family":"Qadri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,12,10]]},"reference":[{"issue":"1","key":"1301_CR1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1182\/asheducation-2002.1.193","volume":"2002","author":"NE Kay","year":"2002","unstructured":"Kay NE, Hamblin TJ, Jelinek DF, Dewald GW, Byrd JC, Farag S, Lucas M, Lin T (2002) Chronic lymphocytic leukemia. Hematology 2002(1):193\u2013213","journal-title":"Hematology"},{"issue":"8","key":"1301_CR2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1470-2045(03)01171-9","volume":"4","author":"O Guipaud","year":"2003","unstructured":"Guipaud O, Deriano L, Salin H, Vallat L, Sabatier L, Merle-B\u00e9ral H, Delic J (2003) B-cell chronic lymphocytic leukaemia: a polymorphic family unified by genomic features. Lancet Oncol 4(8):505\u2013514","journal-title":"Lancet Oncol"},{"issue":"8","key":"1301_CR3","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","volume":"352","author":"N Chiorazzi","year":"2005","unstructured":"Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med 352(8):804\u2013815","journal-title":"N Engl J Med"},{"issue":"4","key":"1301_CR4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00062752-200007000-00005","volume":"7","author":"TJ Kipps","year":"2000","unstructured":"Kipps TJ (2000) Chronic lymphocytic leukemia. Curr Opin Hematol 7(4):223\u2013234","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"1301_CR5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.1999.17.1.399","volume":"17","author":"F Caligaris-Cappio","year":"1999","unstructured":"Caligaris-Cappio F, Hamblin TJ (1999) B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 17(1):399\u2013408","journal-title":"J Clin Oncol"},{"issue":"8","key":"1301_CR6","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/sj.leu.2403398","volume":"18","author":"S Cuni","year":"2004","unstructured":"Cuni S, Perez-Aciego P, Perez-Chacon G, Vargas J, Sanchez A, Martin-Saavedra F, Ballester S, Garcia-Marco J, Jorda J, Durantez A (2004) A sustained activation of PI3\u00a0K\/NF-B pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 18(8):1391\u20131400","journal-title":"Leukemia"},{"issue":"3","key":"1301_CR7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0301-472X(02)01046-9","volume":"31","author":"A Zaninoni","year":"2003","unstructured":"Zaninoni A, Imperiali FG, Pasquini C, Zanella A, Barcellini W (2003) Cytokine modulation of nuclear factor-[kappa] B activity in B-chronic lymphocytic leukemia. Exp Hematol 31(3):185\u2013190","journal-title":"Exp Hematol"},{"issue":"7","key":"1301_CR8","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1182\/blood.V91.7.2387","volume":"91","author":"L Lagneaux","year":"1998","unstructured":"Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P (1998) Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 91(7):2387\u20132396","journal-title":"Blood"},{"issue":"2","key":"1301_CR9","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/blood-2006-06-027755","volume":"109","author":"T Endo","year":"2007","unstructured":"Endo T, Nishio M, Enzler T, Cottam HB, Fukuda T, James DF, Karin M, Kipps TJ (2007) BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-{kappa} B pathway. Blood 109(2):703\u2013710","journal-title":"Blood"},{"key":"1301_CR10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0065-230X(00)79005-1","volume":"79","author":"P Ghia","year":"2000","unstructured":"Ghia P, Caligaris-Cappio F (2000) The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms. Adv Cancer Res 79:157\u2013173","journal-title":"Adv Cancer Res"},{"issue":"10","key":"1301_CR11","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1182\/blood.V99.10.3742","volume":"99","author":"R Hubmann","year":"2002","unstructured":"Hubmann R, Schwarzmeier JD, Shehata M, Hilgarth M, Duechler M, Dettke M, Berger R (2002) Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia. Blood 99(10):3742\u20133747","journal-title":"Blood"},{"issue":"2","key":"1301_CR12","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2141.1995.tb03314.x","volume":"89","author":"S Fournier","year":"1995","unstructured":"Fournier S, Yang L, Delespesse G, Rubio M, Biron G, Sarfati M (1995) The two CD23 isoforms display differential regulation in chronic lymphocytic leukaemia. Br J Haematol 89(2):373\u2013379","journal-title":"Br J Haematol"},{"key":"1301_CR13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1084-9521(02)00183-0","volume":"14","author":"K Ohishi","year":"2003","unstructured":"Ohishi K, Katayama N, Shiku H, Varnum-Finney B, Bernstein I (2003) Notch signalling in hematopoiesis. Semin Cell Develop Biol 14:143\u2013150","journal-title":"Semin Cell Develop Biol"},{"issue":"5415","key":"1301_CR14","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.284.5415.770","volume":"284","author":"S Artavanis-Tsakonas","year":"1999","unstructured":"Artavanis-Tsakonas S, Rand MD, Lake RJ (1999) Notch signaling: cell fate control and signal integration in development. Science 284(5415):770\u2013776","journal-title":"Science"},{"issue":"8","key":"1301_CR15","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1182\/blood.V93.8.2431","volume":"93","author":"LA Milner","year":"1999","unstructured":"Milner LA, Bigas A (1999) Notch as a mediator of cell fate determination in hematopoiesis: evidence and speculation. Blood 93(8):2431\u20132448","journal-title":"Blood"},{"issue":"6","key":"1301_CR16","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1182\/blood-2005-08-3329","volume":"107","author":"KG Leong","year":"2006","unstructured":"Leong KG, Karsan A (2006) Recent insights into the role of Notch signaling in tumorigenesis. Blood 107(6):2223\u20132233","journal-title":"Blood"},{"issue":"3","key":"1301_CR17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6","volume":"181","author":"L Miele","year":"1999","unstructured":"Miele L, Osborne B (1999) Arbiter of differentiation and death: notch signaling meets apoptosis. J Cell Physiol 181(3):393\u2013409","journal-title":"J Cell Physiol"},{"issue":"2","key":"1301_CR18","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0092-8674(02)00689-X","volume":"109","author":"D Allman","year":"2002","unstructured":"Allman D, Punt JA, Izon DJ, Aster JC, Pear WS (2002) An invitation to T and more: notch signaling in lymphopoiesis. Cell 109(2):S1\u2013S11","journal-title":"Cell"},{"issue":"Pt 6","key":"1301_CR19","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1242\/jcs.115.6.1095","volume":"115","author":"R Kopan","year":"2002","unstructured":"Kopan R (2002) Notch: a membrane-bound transcription factor. J Cell Sci 115(Pt 6):1095\u20131097","journal-title":"J Cell Sci"},{"issue":"20","key":"1301_CR20","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1242\/dev.124.20.4133","volume":"124","author":"H Kato","year":"1997","unstructured":"Kato H, Taniguchi Y, Kurooka H, Minoguchi S, Sakai T, Nomura-Okazaki S, Tamura K, Honjo T (1997) Involvement of RBP-J in biological functions of mouse Notch1 and its derivatives. Development 124(20):4133\u20134141","journal-title":"Development"},{"key":"1301_CR21","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/377355a0","volume":"377","author":"S Jarriault","year":"1995","unstructured":"Jarriault S, Brou C, Logeat F, Schroeter EH, Kopan R, Israel A (1995) Signalling downstream of activated mammalian Notch. Nature 377:355\u2013358","journal-title":"Nature"},{"issue":"6683","key":"1301_CR22","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/30756","volume":"393","author":"EH Schroeter","year":"1998","unstructured":"Schroeter EH, Kisslinger JA, Kopan R (1998) Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature 393(6683):382\u2013386","journal-title":"Nature"},{"issue":"1","key":"1301_CR23","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1749-6632.2000.tb06926.x","volume":"920","author":"O Berezovska","year":"2000","unstructured":"Berezovska O, Jack C, McLEAN P, Aster JC, Hicks C, Xia W, Wolfe MS, Weinmaster G, Selkoe DJ, Hyman BT (2000) Rapid Notch1 nuclear translocation after ligand binding depends on presenilin associated secretase activity. Ann N Y Acad Sci 920(1):223\u2013226","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"1301_CR24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1006\/dbio.2000.9960","volume":"228","author":"JS Mumm","year":"2000","unstructured":"Mumm JS, Kopan R (2000) Notch signaling: from the outside in. Dev Biol 228(2):151\u2013165","journal-title":"Dev Biol"},{"issue":"1","key":"1301_CR25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1182\/asheducation-2004.1.163","volume":"2004","author":"JC Byrd","year":"2004","unstructured":"Byrd JC, Stilgenbauer S, Flinn IW (2004) Chronic lymphocytic leukemia. Hematology 2004(1):163\u2013183","journal-title":"Hematology"},{"key":"1301_CR26","unstructured":"Institute NC (2011) Chronic lymphocytic leukemia (PDQ) treatment: stage information. National Institutes of Health. http:\/\/www.cancer.gov\/cancertopics\/pdq\/treatment\/CLL\/healthprofessional\/page2 . Accessed 22 Feb 2011"},{"issue":"4","key":"1301_CR27","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.2008.16.4459","volume":"27","author":"N Lamanna","year":"2009","unstructured":"Lamanna N, Jurcic JG, Noy A, Maslak P, Gencarelli AN, Panageas KS, Heaney ML, Brentjens RJ, Golde DW, Scheinberg DA (2009) Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol 27(4):491\u2013497","journal-title":"J Clin Oncol"},{"issue":"4","key":"1301_CR28","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","volume":"112","author":"CS Tam","year":"2008","unstructured":"Tam CS, O\u2019Brien S, Wierda W, Kantarjian H, Wen S, Do KA, Thomas DA, Cortes J, Lerner S, Keating MJ (2008) Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112(4):975\u2013980","journal-title":"Blood"},{"issue":"22","key":"1301_CR29","doi-asserted-by":"crossref","first-page":"A-536","DOI":"10.1182\/blood.V114.22.536.536","volume":"114","author":"K Rai","year":"2009","unstructured":"Rai K, Peterson B, Appelbaum F, Tallman M, Belch A, Morrison V (2009) Long-term survival analysis of the North American Intergroup Study C9011 comparing fludarabine (F) and chlorambucil (C) in previously untreated patients with chronic lymphocytic leukemia (CLL). Blood 114(22):A-536","journal-title":"Blood"},{"key":"1301_CR30","doi-asserted-by":"crossref","unstructured":"Hallek M, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Gruenhagen U, Bergmann MA (2009) First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R)(FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL study group clinically relevant abstract. Blood 144: 223\u2013224","DOI":"10.1182\/blood.V114.22.535.535"},{"key":"1301_CR31","doi-asserted-by":"crossref","unstructured":"Developments in the treatment of lymphoproliferative disorders: rising to the new challenges of CLL therapy. A report of a symposium presented during the 48th American Society of Hematology Annual Meeting and Exposition, December 8, 2006, Orlando, Florida (2007). Clin Adv Hematol Oncol. 5(3):1\u201314; quiz 15\u201316","DOI":"10.1016\/S1470-2045(06)71002-6"},{"issue":"4","key":"1301_CR32","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood-2005-02-0819","volume":"107","author":"E Montserrat","year":"2006","unstructured":"Montserrat E, Moreno C, Esteve J, Urbano-Ispizua A, Gine E, Bosch F (2006) How I treat refractory CLL. Blood 107(4):1276\u20131283","journal-title":"Blood"},{"issue":"2","key":"1301_CR33","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2006-05-020735","volume":"109","author":"JC Byrd","year":"2007","unstructured":"Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, Moran M, Blum KA, Rovin B, Brooker-McEldowney M (2007) Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109(2):399\u2013404","journal-title":"Blood"},{"issue":"35","key":"1301_CR34","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1200\/JCO.2009.22.6944","volume":"27","author":"TS Lin","year":"2009","unstructured":"Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA, Blum KA, Flynn JM, Jones JA, Hu W (2009) Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 27(35):6012\u20136018","journal-title":"J Clin Oncol"},{"issue":"34","key":"1301_CR35","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1200\/JCO.2005.05.0401","volume":"24","author":"A Chanan-Khan","year":"2006","unstructured":"Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P (2006) Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 24(34):5343\u20135349","journal-title":"J Clin Oncol"},{"issue":"15","key":"1301_CR36","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.2007.13.9709","volume":"26","author":"LA Andritsos","year":"2008","unstructured":"Andritsos LA, Johnson AJ, Lozanski G, Blum W, Kefauver C, Awan F, Smith LL, Lapalombella R, May SE, Raymond CA (2008) Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 26(15):2519\u20132525","journal-title":"J Clin Oncol"},{"issue":"24","key":"1301_CR37","doi-asserted-by":"crossref","first-page":"5788","DOI":"10.1200\/JCO.2005.03.962","volume":"23","author":"SZ Pavletic","year":"2005","unstructured":"Pavletic SZ, Khouri IF, Haagenson M, King RJ, Bierman PJ, Bishop MR, Carston M, Giralt S, Molina A, Copelan EA (2005) Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research. J Clin Oncol 23(24):5788\u20135794","journal-title":"J Clin Oncol"},{"issue":"6","key":"1301_CR38","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/sj.leu.2403745","volume":"19","author":"P Dreger","year":"2005","unstructured":"Dreger P, Brand R, Milligan D, Corradini P, Finke J, Deliliers GL, Martino R, Russell N, Van Biezen A, Michallet M (2005) Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia 19(6):1029\u20131033","journal-title":"Leukemia"},{"issue":"15","key":"1301_CR39","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1200\/JCO.2005.04.531","volume":"23","author":"C Moreno","year":"2005","unstructured":"Moreno C, Villamor N, Colomer D, Esteve J, Martino R, Nomded\u00e9u J, Bosch F, L\u00f3pez-Guillermo A, Campo E, Sierra J (2005) Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 23(15):3433\u20133438","journal-title":"J Clin Oncol"},{"issue":"10","key":"1301_CR40","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","volume":"99","author":"MJ Keating","year":"2002","unstructured":"Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99(10):3554\u20133561","journal-title":"Blood"},{"issue":"1","key":"1301_CR41","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0003-2697(87)90021-2","volume":"162","author":"P Chomczynski","year":"1987","unstructured":"Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162(1):156\u2013159","journal-title":"Anal Biochem"},{"issue":"13","key":"1301_CR42","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","volume":"82","author":"P Skehan","year":"1990","unstructured":"Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82(13):1107\u20131112","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1301_CR43","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2407-6-77","volume":"6","author":"Z Xie","year":"2006","unstructured":"Xie Z, Yuan H, Yin Y, Zeng X, Bai R, Glazer RI (2006) 3-Phosphoinositide-dependent protein kinase-1(PDK 1) promotes invasion and activation of matrix metalloproteinases. BMC Cancer 6(1):77","journal-title":"BMC Cancer"},{"issue":"20","key":"1301_CR44","doi-asserted-by":"crossref","first-page":"7790","DOI":"10.1073\/pnas.86.20.7790","volume":"86","author":"S Agrawal","year":"1989","unstructured":"Agrawal S, Ikeuchi T, Sun D, Sarin PS, Konopka A, Maizel J, Zamecnik PC (1989) Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues. Proc Natl Acad Sci USA 86(20):7790\u20137794","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"1301_CR45","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1074-7613(03)00325-X","volume":"19","author":"I Maillard","year":"2003","unstructured":"Maillard I, Adler S, Pear W (2003) Notch and the immune system. Immunity 19(6):781\u2013791","journal-title":"Immunity"},{"issue":"3","key":"1301_CR46","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/nprot.2006.179","volume":"1","author":"V Vichai","year":"2006","unstructured":"Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1(3):1112\u20131116","journal-title":"Nat Protoc"},{"issue":"12","key":"1301_CR47","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-09-2823","volume":"16","author":"A Pannuti","year":"2010","unstructured":"Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B, Miele L (2010) Targeting notch to target cancer stem cells. Clin Cancer Res 16(12):3141\u20133152. doi: 10.1158\/1078-0432.ccr-09-2823","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1301_CR48","first-page":"3357","volume":"5","author":"AR Yuen","year":"1999","unstructured":"Yuen AR, Halsey J, Fisher GA, Holmlund JT, Geary RS, Kwoh TJ, Dorr A, Sikic BI (1999) Phase I study of an antisense oligonucleotide to protein kinase C-(ISIS 3521\/CGP 64128A) in patients with cancer. Clin Cancer Res 5(11):3357\u20133363","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1301_CR49","first-page":"288","volume":"3","author":"R Orr","year":"2001","unstructured":"Orr R (2001) Technology evaluation: fomivirsen, isis pharmaceuticals Inc\/CIBA vision. Curr Opin Mol Ther 3(3):288\u2013294","journal-title":"Curr Opin Mol Ther"},{"issue":"1","key":"1301_CR50","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0167-4781(99)00148-7","volume":"1489","author":"ST Crooke","year":"1999","unstructured":"Crooke ST (1999) Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta 1489(1):31\u201344","journal-title":"Biochim Biophys Acta"},{"issue":"9","key":"1301_CR51","doi-asserted-by":"crossref","first-page":"7108","DOI":"10.1074\/jbc.M210326200","volume":"278","author":"TA Vickers","year":"2003","unstructured":"Vickers TA, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF (2003) Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. J Biol Chem 278(9):7108\u20137118","journal-title":"J Biol Chem"},{"issue":"4","key":"1301_CR52","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood-2008-02-139725","volume":"113","author":"E Rosati","year":"2009","unstructured":"Rosati E, Sabatini R, Rampino G, Tabilio A, Di Ianni M, Fettucciari K, Bartoli A, Coaccioli S, Screpanti I, Marconi P (2009) Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood 113(4):856\u2013865","journal-title":"Blood"},{"issue":"10","key":"1301_CR53","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S0006-2952(97)82440-9","volume":"53","author":"GD Gray","year":"1997","unstructured":"Gray GD, Basu S, Wickstrom E (1997) Transformed and immortalized cellular uptake of oligodeoxynucleoside phosphorothioates, 3\u2032-alkylamino oligodeoxynucleotides, 2\u2032-O-methyl oligoribonucleotides, oligodeoxynucleoside methylphosphonates, and peptide nucleic acids. Biochem Pharmacol 53(10):1465\u20131476","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"1301_CR54","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0026-895X(25)09229-6","volume":"41","author":"CF Bennett","year":"1992","unstructured":"Bennett CF, Chiang MY, Chan H, Shoemaker J, Mirabelli CK (1992) Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 41(6):1023\u20131033","journal-title":"Mol Pharmacol"},{"issue":"18","key":"1301_CR55","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1021\/bi00069a022","volume":"32","author":"C Stein","year":"1993","unstructured":"Stein C, Tonkinson JL, Zhang LM, Yakubov L, Gervasoni J, Taub R, Rotenberg SA (1993) Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells. Biochemistry 32(18):4855\u20134861","journal-title":"Biochemistry"},{"issue":"5","key":"1301_CR56","first-page":"347","volume":"1","author":"N Dias","year":"2002","unstructured":"Dias N, Stein C (2002) Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 1(5):347\u2013355","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"1301_CR57","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nm0696-668","volume":"2","author":"BP Monia","year":"1996","unstructured":"Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D (1996) Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med 2(6):668\u2013675","journal-title":"Nat Med"},{"issue":"1","key":"1301_CR58","first-page":"13","volume":"6","author":"TA Bacon","year":"1991","unstructured":"Bacon TA, Wickstrom E (1991) Walking along human c-myc mRNA with antisense oligodeoxynucleotides: maximum efficacy at the 5\u2032 cap region. Oncogene Res 6(1):13\u201319","journal-title":"Oncogene Res"},{"issue":"22","key":"1301_CR59","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.1073\/pnas.84.22.7896","volume":"84","author":"P Dash","year":"1987","unstructured":"Dash P, Lotan I, Knapp M, Kandel ER, Goelet P (1987) Selective elimination of mRNAs in vivo: complementary oligodeoxynucleotides promote RNA degradation by an RNase H-like activity. Proc Natl Acad Sci USA 84(22):7896\u20137900","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"1301_CR60","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1073\/pnas.85.14.5011","volume":"85","author":"RY Walder","year":"1988","unstructured":"Walder RY, Walder JA (1988) Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci USA 85(14):5011\u20135015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"1301_CR61","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.bbrc.2004.01.095","volume":"315","author":"L Sanz","year":"2004","unstructured":"Sanz L, Garcia-Marco JA, Casanova B, de la Fuente MI (2004) Bcl-2 family gene modulation during spontaneous apoptosis of B-chronic lymphocytic leukemia cells. Biochem Biophys Res Commun 315(3):562\u2013567","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1301_CR62","doi-asserted-by":"crossref","first-page":"E61","DOI":"10.1208\/aapsj070109","volume":"7","author":"SD Patil","year":"2005","unstructured":"Patil SD, Rhodes DG, Burgess DJ (2005) DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J 7(1):E61\u2013E77","journal-title":"AAPS J"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-011-1301-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11033-011-1301-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-011-1301-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T09:11:30Z","timestamp":1742029890000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11033-011-1301-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,10]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["1301"],"URL":"https:\/\/doi.org\/10.1007\/s11033-011-1301-5","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"type":"print","value":"0301-4851"},{"type":"electronic","value":"1573-4978"}],"subject":[],"published":{"date-parts":[[2011,12,10]]}}}